CLOSEOUT LETTER
Oakdell Pharmacy, Inc
- Recipient:
- Oakdell Pharmacy, Inc
United States
- Issuing Office:
United States
Office of Pharmaceutical Quality Operations, Division II | |
December 21, 2017
Mr. John J. Carson, R.Ph.
Chief-of-Staff
Oakdell Pharmacy, LLC
7220 Louis Pasteur Drive, Suite 176
San Antonio, TX 78229-4535
Mr. Carson:
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [Ref: 2014-DAL-WL-04 dated May 27, 2014]. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
If you have additional questions, please contact Thao Ta, Compliance Officer, at 214-253-5217, or by email at Thao.Ta@fda.hhs.gov.
Sincerely,
/S/
John Diehl
Acting Director, Compliance Branch
Office of Pharmaceutical Quality Operations, Division II